ONCOLOGY: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes

Audio Journal of Oncology, December 9th, 2007 Reporting from: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes PIERRE FENAUX, Paris 13 University REFERENCE: ABSTRACT 817, ASH 2007 Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University gave the details to Derek Thorne.